Zohra Oum'Hamed - Concepedia

Author

Zohra Oum'Hamed

Also Known As

Z Oum'Hamed, Z Oum'hamed, Z OumʼHamed, Z. Oum'Hamed, Z. Oum'hamed, Z. Oum’Hamed, Z. Oum’hamed, Zohra Oum'Hamed, Zohra Oum’hamed

Publications

437

Citations

H-Index

Concepts

All Affiliations

Université de Reims Champagne-Ardenne Boehringer Ingelheim (Germany)Boehringer Ingelheim (Austria)Centre Hospitalier Universitaire de Reims Vall d'Hebron Hospital Universitari

About

Zohra Oum'Hamed is an author at Université de Reims Champagne-Ardenne specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	148
2	Engineering	1	1	12
3	Biomedical Engineering	1	1	12
4	Cell Biology	1	1	12
5	Immunology	1	1	47

Zohra Oum'Hamed

Publications

398

Citations

H-Index

Page 1

	Year	Citations
In vitro reactions of human osteoblasts in culture with zirconia and alumina ceramics Y. Josset, Zohra Oum'Hamed, A. Zarrinpour, Journal of Biomedical Materials Research	1999	158
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study Eric Van Cutsem, Takayuki Yoshino, Heinz‐Josef Lenz, Annals of Oncology	2018	63
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). Martin Wermke, Enriqueta Felip, Yasutoshi Kuboki, Journal of Clinical Oncology ImmunologyDll3+ CellsInhibitory Notch LigandImmunotherapyTumor Biology	2023	47
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients Eric Van Cutsem, Hans Prenen, Geert D’Haens, Annals of Oncology OncologyMedicineColorectal CancerMfolfox6 Versus BevacizumabCancer Treatment	2015	40
Matrix metalloproteinases MMP‐2, ‐9 and tissue inhibitors TIMP‐1, ‐2 expression and secretion by primary human osteoblast cells in response to titanium, zirconia, and alumina ceramics Zohra Oum'Hamed, Roselyne Garnotel, Y. Josset, Journal of Biomedical Materials Research Part A	2003	29
Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment Eric Van Cutsem, Takayuki Yoshino, Julia Hocke, Clinical Colorectal Cancer MedicineCancer ManagementStandard TreatmentColorectal CancerSurgery	2015	27
A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer Eric Van Cutsem, Hans Prenen, Carmen Guillén‐Ponce, European Journal of Cancer OncologyMedicinePathologyColorectal CancerMetastatic Colorectal Cancer	2011	22
DNA image cytometry and Ag-NORs-staining application in biocompatibility studies on human osteoblast cells in vitro Y. Josset, Zohra Oum'Hamed, A. Zarrinpour, Biomaterials Tissue EngineeringBone ImagingEngineeringMedicineHuman Tissue	1998	12

Page 1